Skip to main content

Table 2 Multivariate analysis of predictors for OS and LCSS

From: Propensity score-matching analysis of postoperative radiotherapy for stage IIIA-N2 non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database

Variable

Before PSM

After PSM

OS

LCSS

OS

LCSS

Hazard ratio (95% CI)

p

Hazard ratio (95% CI)

p

Hazard ratio (95% CI)

p

Hazard ratio (95% CI)

p

Age (versus <60 years)

 60–79 years

0.822 (0.742–0.911)

0.000

0.809 (0.723–0.904)

0.000

0.758 (0.648–0.887)

0.001

0.716 (0.604–0.850)

0.000

 ≥80 years

1.007 (0.844–1.201)

0.938

1.059 (0.878–1.277)

0.548

0.962 (0.730–1.267)

0.781

0.977 (0.727–1.313)

0.876

Gender (versus Male)

1.066 (0.974–1.168)

0.163

1.049 (0.951–1.158)

0.337

1.030 (0.895–1.186)

0.676

1.030 (0.884–1.202)

0.703

Race (versus White)

1.033 (0.923–1.157)

0.570

1.043 (0.922–1.179)

0.504

1.085 (0.912–1.291)

0.357

1.108 (0.917–1.339)

0.289

Marital status (versus Married)

1.001 (0.912–1.099)

0.984

0.966 (0.872–1.070)

0.511

1.160 (1.000–1.344)

0.049

1.173 (0.999–1.378)

0.052

Insurance (versus insured)

0.970 (0.883–1.065)

0.519

0.995 (0.899–1.101)

0.924

0.844 (0.730–0.977)

0.023

0.877 (0.748–1.027)

0.104

Laterality (versus left)

1.021 (0.929–1.121)

0.671

1.061 (0.958–1.175)

0.257

1.048 (0.906–1.212)

0.530

1.107 (0.943–1.298)

0.213

Location (versus upper lobe)

 Lower lobe

1.025 (0.812–1.294)

0.834

1.027 (0.800–1.317)

0.835

1.137 (0.807–1.601)

0.463

1.076 (0.737–1.570)

0.706

 Middle lobe

1.059 (0.960–1.167)

0.251

1.024 (0.921–1.139)

0.660

0.996 (0.857–1.158)

0.961

0.958 (0.813–1.130)

0.612

Tumor size

1.005 (1.003–1.008)

0.000

1.006 (1.003–1.008)

0.000

1.007 (1.003–1.012)

0.000

1.009 (1.005–1.014)

0.000

Regional LN positive

1.034 (1.014–1.054)

0.001

1.040 (1.019–1.062)

0.000

1.053 (1.020–1.087)

0.002

1.069 (1.033–1.107)

0.000

Regional LN examined

0.995 (0.987–1.004)

0.261

0.993 (0.984–1.002)

0.136

0.994 (0.981–1.007)

0.370

0.988 (0.973–1.003)

0.121

% of LN positive

1.902 (1.490–2.429)

0.000

1.965 (1.507–2.562)

0.000

1.562 (1.041–2.342)

0.031

1.560 (0.997–2.439)

0.051

Histology (versus Adenocarcinoma)

 Squamous cell carcinoma

1.183 (1.058–1.323)

0.003

1.133 (1.002–1.282)

0.046

1.278 (1.077–1.516)

0.005

1.213 (1.004–1.467)

0.045

 Adenosquamous and Large cell carcinoma

1.278 (1.069–1.527)

0.007

1.300 (1.073–1.575)

0.007

1.256 (0.964–1.637)

0.092

1.335 (1.007–1.771)

0.045

Differentiation grade (versus Well differentiated)

 Moderately differentiated

1.118 (0.901–1.387)

0.310

1.149 (0.906–1.458)

0.251

1.051 (0.703–1.570)

0.809

1.117 (0.717–1.741)

0.625

 Poorly differentiated

1.245 (1.002–1.546)

0.048

1.284 (1.011–1.631)

0.041

1.168 (0.781–1.745)

0.449

1.238 (0.794–1.929)

0.346

 Undifferentiated

1.371 (0.969–1.942)

0.075

1.377 (0.940–2.018)

0.101

1.434 (0.799–2.571)

0.227

1.526 (0.809–2.880)

0.192

Surgical procedure (versus Sublobectomy)

 Lobectomy

0.786 (0.664–0.930)

0.005

0.769 (0.641–0.922)

0.005

0.659 (0.500–0.868)

0.003

0.613 (0.456–0.825)

0.001

 Pneumonectomy

0.778 (0.619–0.978)

0.032

0.757 (0.590–0.970)

0.028

0.515 (0.344–0.771)

0.001

0.487 (0.315–0.753)

0.001

T stage (sixth edition) (versus T1)

 T2

1.224 (1.090–1.375)

0.001

1.224 (1.078–1.390)

0.002

1.165 (0.971–1.397)

0.100

1.160 (0.950–1.417)

0.145

 T3

1.816 (1.477–2.233)

0.000

1.960 (1.574–2.440)

0.000

1.747 (1.249–2.443)

0.001

1.812 (1.263–2.598)

0.001

PORT (versus No PORT)

0.846 (0.769–0.932)

0.001

0.838 (0.755–0.931)

0.001

0.793 (0.690–0.912)

0.001

0.837 (0.719–0.975)

0.022

  1. LN lymph node, PSM propensity score-matching, OS overall survival, LCSS lung cancer specific survival, PORT postoperative radiotherapy, CI confidence interval